SCHEMBL1309254

SCHEMBL1309254

CC1CCCCN1c1cccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 3/20 0.51
▸ NPSR1 Q6W5P4 2/20 0.51
▸ ASIC3 Q9UHC3 1/20 0.47
▸ KDM4E B2RXH2 2/20 0.44
▸ MAPT P10636 2/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ TSHR P16473 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.41
▸ ALOX15 P16050 2/20 0.41
▸ LMNA P02545 2/20 0.41
▸ USP2 O75604 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ MTOR P42345 6/20 0.41
▸ PIK3CA P42336 4/20 0.40
▸ PIK3R1 P27986 2/20 0.40
▸ SYK P43405 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1310137 0.82 NPSR1 (0.48) MAPK1NPSR1MTORPIK3CAPIK3R1
SCHEMBL18117900 0.82 ALDH1A1 (0.49) MAPK1NPSR1KDM4EMAPTL3MBTL1
SCHEMBL1309804 0.81 KDM4E (0.52) MAPK1NPSR1KDM4EMAPTTSHR
SCHEMBL1309518 0.81 TSHR (0.48) MAPK1NPSR1KDM4EMAPTTSHR
SCHEMBL18117927 0.80 ALDH1A1 (0.54) MAPK1NPSR1KDM4EMAPTTSHR
SCHEMBL18117923 0.80 ALDH1A1 (0.54) MAPK1NPSR1KDM4EMAPTTSHR
SCHEMBL1310491 0.80 ALDH1A1 (0.54) MAPK1NPSR1KDM4EMAPTTSHR
SCHEMBL18117891 0.80 ALDH1A1 (0.54) MAPK1NPSR1KDM4EMAPTTSHR
SCHEMBL18117947 0.80 ALDH1A1 (0.45) MAPK1NPSR1KDM4EMAPTTSHR
SCHEMBL1310324 0.80 PIK3CA (0.51) MAPK1NPSR1KDM4EMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364302-B1 TRIAZINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIV BASEL (CH) 2016-10-05 — — EP disclosed
US-8921361-B2 Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes UNIVERSITY OF BASEL (CH) 2014-12-30 — — US disclosed
US-8921361-B2 Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes UNIVERSITY OF BASEL (CH) 2014-12-30 — — US disclosed
US-8921361-B2 Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes UNIVERSITY OF BASEL (CH) 2014-12-30 — — US disclosed
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2011-11-10 — — US disclosed
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2011-11-10 — — US disclosed
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2011-11-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES MTOR, PIK3CA, PIK3CD MAPK1 216/4885NPSR1 1950/4885ASIC3 2181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback